Skip to main content
Journal cover image

Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target.

Publication ,  Journal Article
Darabi, S; Xiu, J; Samec, T; Kesari, S; Carrillo, J; Aulakh, S; Walsh, KM; Sengupta, S; Sumrall, A; Spetzler, D; Glantz, M; Demeure, MJ
Published in: Med Oncol
June 8, 2023

Gliomas are the most prevalent neurological cancer in the USA and care modalities are not able to effectively combat these aggressive malignancies. Identifying new, more effective treatments require a deep understanding of the complex genetic variations and relevant pathway associations behind these cancers. Drawing connections between gene mutations with a responsive genetic target can help drive therapy selections to enhance patient survival. We have performed extensive molecular profiling of the Capicua gene (CIC), a tumor and transcriptional suppressor gene, and its mutation prevalence in reference to MAPK activation within clinical glioma tissue. CIC mutations occur far more frequently in oligodendroglioma (52.1%) than in low-grade astrocytoma or glioblastoma. CIC-associated mutations were observed across all glioma subtypes, and MAPK-associated mutations were most prevalent in CIC wild-type tissue regardless of the glioma subtype. MAPK activation, however, was enhanced in CIC-mutated oligodendroglioma. The totality of our observations reported supports the use of CIC as a relevant genetic marker for MAPK activation. Identification of CIC mutations, or lack thereof, can assist in selecting, implementing, and developing MEK/MAPK-inhibitory trials to improve patient outcomes potentially.

Duke Scholars

Published In

Med Oncol

DOI

EISSN

1559-131X

Publication Date

June 8, 2023

Volume

40

Issue

7

Start / End Page

197

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Repressor Proteins
  • Oncology & Carcinogenesis
  • Oligodendroglioma
  • Mutation
  • Humans
  • Glioma
  • Brain Neoplasms
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Darabi, S., Xiu, J., Samec, T., Kesari, S., Carrillo, J., Aulakh, S., … Demeure, M. J. (2023). Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target. Med Oncol, 40(7), 197. https://doi.org/10.1007/s12032-023-02071-0
Journal cover image

Published In

Med Oncol

DOI

EISSN

1559-131X

Publication Date

June 8, 2023

Volume

40

Issue

7

Start / End Page

197

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Repressor Proteins
  • Oncology & Carcinogenesis
  • Oligodendroglioma
  • Mutation
  • Humans
  • Glioma
  • Brain Neoplasms
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis